Wellcome fails to calm City fears
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.WELLCOME'S attempt to regain the initiative over the effectiveness of its AZT anti-Aids drug backfired yesterday after a stormy presentation to the City, writes Gail Counsell.
The meeting was called to cast doubt on the preliminary conclusions of a recent Anglo-French trial that the drug, marketed as Retrovir, was of no use to asymptomatic patients - those who are HIV positive but have not yet developed Aids.
The share price had risen in anticipation of a strong rebuttal. But analysts described the presentation as 'unconvincing' and 'a PR disaster' and the shares dipped sharply before recovering slightly to end down 23p at 698p.
'The net result was very confusing. We won't be in a position to conclude anything until the study is properly published and peer reviewed,' said Jonathan de Pass, a BZW analyst.
Wellcome's main complaint about the Anglo-French Concorde study is that Retrovir was used by some of a group of asymptomatic patients who were not supposed to take the drug until they developed Aids. The group said other larger studies demonstrated the effectiveness of early use of Retrovir.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments